Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5429083 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part A: RO5429083 | EXPERIMENTAL | - |
| Part B: RO5429083 + cytarabine | EXPERIMENTAL | - |
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO5429083 | DRUG | Multiple escalating doses |
| cytarabine | DRUG | 1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles |
Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically or cytologically confirmed, acute myelogenous leukemia (all subtypes except acute promyelotic leukemia) according to WHO criteria * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 * All non-hematological...
RO5429083 is an investigational small molecule being studied for the treatment of acute myelogenous leukemia and other neoplasms, specifically in patients with CD44-expressing malignant solid tumors. It is being developed by Roche Holding AG (RHHBY) and is currently in Phase 1 clinical development.
RO5429083 targets CD44, a cell surface glycoprotein involved in cell adhesion and signaling. It is being studied in patients with CD44-expressing malignant solid tumors, as well as in acute myelogenous leukemia. The drug is designed to interfere with CD44-mediated pathways in cancer cells.
RO5429083 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in oncology indications, including acute myelogenous leukemia and solid tumors.
RO5429083 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, one in solid tumors and one in acute myelogenous leukemia, but the drug remains in early-stage clinical testing.
RO5429083 has been studied in two completed Phase 1 trials. NCT01358903 evaluated the drug in patients with metastatic or locally advanced CD44-expressing malignant solid tumors, enrolling 65 participants in the United States, France, and the Netherlands. NCT01641250 studied the drug alone or with cytarabine in acute myelogenous leukemia, enrolling 44 participants in France, Germany, and Italy.
RO5429083 is the primary name for this investigational drug. No alternative names have been reported in clinical trial records. It is identified solely by its compound number, RO5429083, in the studies conducted by Roche.